HUTCHMED (formerly Hutchison China MediTech)

HUTCHMED, known historically as Hutchison China MediTech, is an innovative, commercial-stage biopharmaceutical company focused on discovering and developing targeted therapies and immunotherapies for cancer and immunological diseases. The company describes itself as one of the first global-focused novel drug discovery companies in China. It says that over more than two decades it has built an integrated research and development platform covering drug discovery and development, with the aim of taking candidates from in-house research to patients internationally. The company’s commercial activity combines proprietary oncology medicines with a China-based platform for manufacturing, marketing and distribution. Its official materials describe a portfolio that includes novel oncology products as well as prescription drugs and consumer health products in China. HUTCHMED says its first four medicines have been marketed in China, and that its first medicine has also received approvals internationally, including in the United States, Europe and Japan. The supplied materials identify products and development programs including savolitinib, fruquintinib, sovleplenib and fanregratinib, and highlight clinical research in lung, colorectal, gastric and other cancers, as well as immune thrombocytopenia. HUTCHMED presents its business as spanning discovery, clinical development, regulatory progress and commercial access, while also using licensing and strategic partnerships to advance its pipeline. In September 2026, its website reported a licensing agreement with GSK for a KRAS-EGFR antibody-targeted therapy conjugate. Its site also reported Chinese regulatory and clinical developments, including approval of fanregratinib (ATLED) and phase III results for combinations involving savolitinib. These are company-reported updates and do not imply that every investigational product is approved or commercially available. The company is publicly listed on Nasdaq, the Hong Kong Stock Exchange and the London Stock Exchange’s AIM market. Its website identifies Dr. Weiguo Su as Chief Scientific Officer and as CEO on leave of absence, and Johnny Cheng as Acting CEO and CFO. HUTCHMED states its mission as discovering, developing and bringing innovative medicines to patients worldwide. Its positioning emphasizes science-led innovation, global drug development and access to the Chinese commercial market.

HUTCHMED developed as a China-origin drug discovery and development company with an ambition to bring medicines from in-house research to patients internationally. Its current corporate description emphasizes more than two decades of work and the establishment of an integrated research and development platform. The supplied company materials do not specify the exact founding date, founder or headquarters, so those details are not stated here. The company’s development model combines small-molecule drug discovery and clinical development with commercial operations in China. HUTCHMED says its teams have advanced candidates from internal discovery and that its commercial platform manufactures, markets and distributes oncology products, prescription drugs and consumer health products in China. Its stated focus has expanded across targeted cancer therapies and immunotherapies, alongside medicines for immunological diseases. HUTCHMED reports that its first four medicines have been marketed in China. It also says its first medicine has received approvals in the United States, Europe and Japan, reflecting the company’s stated international development ambitions. The official homepage and company materials name programs including savolitinib, fruquintinib, sovleplenib and fanregratinib, and reference clinical research across several cancer types and immune thrombocytopenia. The evidence provided does not establish a complete product launch chronology, so no unsupported launch dates are assigned. The company’s international development strategy includes collaborations and licensing. In September 2026, HUTCHMED’s homepage reported a licensing agreement with GSK covering a KRAS-EGFR antibody-targeted therapy conjugate. Its site also reported phase III clinical findings for the SANOVO study and Chinese approval of fanregratinib (ATLED) in August 2026. These are time-specific company website reports; clinical results and development announcements should not be read as evidence that all pipeline candidates are approved medicines. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market. The company’s about page identifies its mission as discovering, developing and bringing innovative medicines to patients worldwide. The supplied leadership pages record changes in executive responsibilities: Weiguo Su became CEO in March 2022, took a leave of absence beginning 25 August 2025, and remained identified as Chief Scientific Officer; Johnny Cheng was identified as Acting CEO and CFO from 25 August 2025. This account follows the leadership information and dated company updates in the supplied evidence and does not infer unreported ownership or corporate history.

• Weiguo Su became Chief Executive Officer.

  [4]HUTCHMED - Leadershiphutch-med.com
• Weiguo Su began a leave of absence as CEO; Johnny Cheng became Acting CEO while continuing as CFO.

  [4]HUTCHMED - Leadershiphutch-med.com
• The company reported NMPA approval of ATLED (fanregratinib) for FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.

  [1]HUTCHMED - Homehutch-med.com
• The company reported a progression-free survival benefit in the SANOVO trial of ORPATHYS plus TAGRISSO in China.

  [1]HUTCHMED - Homehutch-med.com
• HUTCHMED announced a licensing agreement with GSK for a KRAS-EGFR antibody-targeted therapy conjugate.

  [1]HUTCHMED - Homehutch-med.com

An innovative, commercial-stage biopharmaceutical company combining in-house drug discovery and global development with a commercial platform and market access in China.

• Savolitinib (ORPATHYS)

  A HUTCHMED medicine referenced in company materials and clinical-development updates.

• Fruquintinib

  A HUTCHMED medicine referenced in company materials, including discussion of global phase III research in refractory metastatic colorectal cancer.

• Sovleplenib

  A HUTCHMED medicine referenced in company materials, including phase III research in primary immune thrombocytopenia in China.

• Fanregratinib (ATLED)

  A medicine for which the company reported NMPA approval in August 2026 for FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.

• 2026

  Imported Cancer Drug Tazverik Withdrawn and Recalled Less Than a Year After Launch Due to Safety Risk

  Because of the risk of secondary hematologic malignancies, which may outweigh the benefits, the cancer drug Tazverik (tazemetostat), introduced by HUTCHMED, initiated market withdrawal, recall, and termination of related clinical trials in China in March 2026; the National Healthcare Security Administration removed it from online listing and from the commercial insurance innovative drug directory.

  Source

Read more

• 2021.06.18

  Reported2021.06.18

  HUTCHMED launches Hong Kong IPO[8]HUTCHMED启动香港首次公开募股finanznachrichten.de

  HUTCHMED said it had launched its Hong Kong initial public offering, comprising a global offering of 104 million new ordinary shares and a proposed primary listing on the Main Board of the Hong Kong Stock Exchange.

Read more

1. 1HUTCHMED - Homehutch-med.com
2. 2HUTCHMED - Corporate Informationhutch-med.com
3. 3HUTCHMED - About Ushutch-med.com
4. 4HUTCHMED - Leadershiphutch-med.com
5. 5Imported Cancer Drug Tazverik Withdrawn and Recalled Less Than a Year After Launch Due to Safety Riskthepaper.cn
6. 6Imported Cancer Drug Tazverik Withdrawn and Recalled Less Than a Year After Launch Due to Safety Riskbjnews.com.cn
7. 7Imported Cancer Drug Tazverik Withdrawn and Recalled Less Than a Year After Launch Due to Safety Riskstcn.com
8. 8HUTCHMED启动香港首次公开募股finanznachrichten.de